Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Ovarian Cancer · Carcinoma, Ovarian Epithelial · Fallopian Tube Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 643 (final count)
- Started
- Dec 13, 2021
- Main results expected
- Mar 5, 2025
- Fully finished
- Jul 16, 2027
- Results posted
- Mar 9, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥1)
Measured over: Up to ~38 months
PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants
Measured over: Up to ~38 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05116189 · record last updated 2026-03-09 · checked 2026-11-09 15:47 UTC